Efficacy across a diverse range of individuals

• Shows great success in groups of adults/adolescents (12 years and older) as well as in children (between 5 and 11 years old), with both groups seeing an around 45% reduction in LDL-C levels compared to the placebo groups.

• Evkeeza showed a similar amount of success in male and female HoFH patients, showing no gender-specific advantages

• The clinical trials also showed clinical success across ethnic groups, but it should be noted that results showed it worked the best in White and Asian participants, but as the sample size of other races was limited, this may not be the case

General safety across the population

While Evkeeza has been generally well-tolerated in clinical trials, there are some side effects. Common side effects include the common cold, influenza-like symptoms, dizziness, runny nose, and nausea. In some cases however, there have been serious hypersensitivity reactions, including anaphylaxis.

_{(Center for Drug Evaluation and Research, 2024)}

Ayalinch: Drug Development & Clinical Trials (Pre-clinical, Further analysis of Phase III)

Kris: Analysis & Outlook & Clinical Trials (Phase I, II, II)

Regeneron could explore creating compound therapies of Evkeeza with PCSK9 inhibitors or statins to enhance LDL-C reduction in HoFH patients. Researching synergistic effects with other lipid-lowering agents may improve treatment protocols for medically complex cases.

Long-Term Safety and Efficacy

Studying the long-term effects of ANGPTL3 inhibition is essential to ensure safety, particularly regarding potential impacts on liver health and metabolism. It is as yet unknown whether long-term inhibition of ANGPLT3 will negatively detriment HoFH patients' health.

Alternative Diseases Tackled by Evkeeza

Evkeeza could be used to target other ANGPTL3-related conditions, such as familial chylomicronemia syndrome (FCS) or nonalcoholic fatty liver disease, could broaden its therapeutic scope.

Administration Improvements

The potential for oral or non-injection administration methods could reduce the burden of intravenous infusions, making treatment more accessible. Alternatively, developing longer-lasting Evkeeza could increase dosage intervals, making the drug more convenient to patients

Cost and Accessibility

Regeneron could promote efforts to expand insurance coverage or patient assistance programs, which improves accessibility for underserved populations that need the drug the most.

Mode of Delivery: VERVE-101 is administered as a single intravenous injection. Specifically, VERVE-101 uses lipid nanoparticles (LNPs) for effective delivery and targeting of the liver.

Advantages:

• VERVE-101 has the potential to be a one-time treatment, as it knocks out the PCSK9 gene, which has shown permanent reduction in LDL-C levels, potentially eliminating the need for other forms of ongoing therapy.

  
  

Disadvantages:

• The long-term safety profile of VERVE-101 is not fully established. Worse yet is that interim clinical trials have seen serious adverse events, including a death.

_{(Verve Therapeutics, n.d.)}

Mode of Delivery: LEQVIO is also via a subcutaneous injection. After the first two doses (which are three months apart), LEQVIO is administered biannually.

(National Center for Biotechnology Information [NCBI], 2023)

- Targets a niche market with minimal competition.

- Annual cost: $450,000.

_{(Regeneron, 2021)}

_{(Regeneron, 2021)}

YES

• Patent Protections: Regeneron Pharmaceuticals, the developer of Evkeeza, holds patents in the USPTO (United States Patent and Trademark Office) and the EPO (European Patent Office). Regeneron has also secured collaborations to further patent its drug in other international patent jurisdictions. Following the USPTO granting Regeneron expanded patent approval, no one can create a biosimilar until 2035. (Federal Register, 2024)

• Unique Mechanism of Action: Evkeeza is a novel monoclonal antibody therapy, that directly binds to ANGPLT3 proteins to inhibit them. As this is a new technology, few competitors have a pipeline to commercialize this class of therapies. (Lu et al., 2020)

NO

• Alternative methods of targeting ANGPLT3: Other pharmaceuticals can use methods developed with their existing pipelines (E.g. Verve Therapeutics' CRISPR + LNP pipeline) and modify them to target the ANGPLT3 gene instead. For the two mentioned competitors (VERVE-101 and LEQVIO), as their methods are nucleotide based, it theoretically would be easier to modify their their drugs to target ANGPLT3 than it would be for Regeneron to make a new antibody to target PSCK9.

Overall, it's safe to say that Regeneron has a decent moat around therapies that target ANGPLT3, as most biopharmaceuticals are still focusing on targeting PSCK9 without any trials being run on ANGPLT3. However, when Regeneron's patent expires in 2035, many competitors are sure to capitalize on this, and produce evinacumab at lower costs to the consumer.

• Skin: xanthomas (fat nodules) form commonly on hands, elbows, knees, and around the eyes

• Tendons: formation of xanthomas may cause thickening of the Achilles tendon as well as in some tendons in the hands 

• Eyes: Fat accumulation can result in corneal arcus, characterized by a white or grey ring around the iris. This seen more often in older individuals but also in younger people with HoFH. 

_{(Mayo Foundation for Medical Education and Research, n.d.)}

Patients were randomized to receive Evkeeza (n=43) or a placebo (n=22) during a 24-week double-blind treatment period, followed by a 24-week open-label extension period (where all patients received Evkeeza)

This study relied on intravenous administration of Evkeeza at a fixed dosage of 15 mg/kg every 4 weeks.

Key Findings:

• Efficacy: At Week 24, the evinacumab group achieved a 47.1% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline, compared to a 1.9% increase in the placebo group (p < 0.001). Additionally, significant reductions in other lipid parameters, including apolipoprotein B and non-high-density lipoprotein cholesterol, were observed in the evinacumab group, but not in the placebo.

• Safety: Once again, Evinacumab was generally well-tolerated, but had the same common adverse events.

Overall, this Phase 3 study showed Evkeeza's significant efficacy in reducing LDL-C levels in HoFH patients when added to standard lipid-lowering therapies, with an acceptable safety profile. Additionally this addition of the open-label extension period boosts Regeneron's adherence to ethical research.

_{(Regeneron Pharmaceuticals, 2023)}

• VelocImmune® Technology: Regeneron utilized its proprietary VelocImmune® platform to create evinacumab. This technology employs genetically humanized mice to produce optimized, fully human monoclonal antibodies, streamlining the development process.

• Clinical Development and Approval: Evinacumab underwent rigorous clinical trials, including the pivotal Phase 3 ELIPSE HoFH study, which demonstrated significant reductions in LDL-C levels in patients with homozygous familial hypercholesterolemia. These positive outcomes led to its approval as an adjunctive therapy for this patient population.

_{(Markham, 2021), (Murphy et al., 2014)}

83 adults with fasting triglyceride levels between 150 and 450 mg/dL and LDL cholesterol levels of at least 100 mg/dL.

Participants were randomized to receive a single ascending dose of evinacumab (subcutaneously at 75, 150, or 250 mg, or intravenously at 5, 10, or 20 mg/kg) or placebo. Then, participants were monitored for up to 126 days post-dosing.

Key Findings:

• Efficacy: Evinacumab administration led to dose-dependent reductions in triglyceride levels, with a maximum reduction of 76.9% observed on day 3 at the 10 mg/kg intravenous dose

  
  

• Safety: The treatment was generally well-tolerated, with no serious adverse events reported. Although some participants experienced transient elevations in liver enzymes (alanine aminotransferase and aspartate aminotransferase) and creatine phosphokinase.

Overall, This Phase 1 trial showed Evkeeza's potential as a lipid-lowering agent, as well as safety, but had yet to focus on targeting HoFH patients.

_{(Ahmad et al., 2019)}

• Boosting Lipid Breakdown: By inhibiting ANGPTL3, Evkeeza enhances the activity of lipase enzymes (lipoprotein lipase and endothelial lipase), which increases the breakdown of triglycerides and very-low-density lipoproteins (VLDL).

• LDL-C Reduction Without LDL Receptors: This process reduces circulating levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides through an LDL receptor-independent mechanism

  
  

• Impact on Cardiovascular Risk: By addressing elevated LDL-C and triglyceride levels, Evkeeza potentially lowers the risk of cardiovascular complications associated with severe hyperlipidemia, providing a much-needed option for patients unresponsive to existing therapies.

_{(Kosmas et al., 2022)}

The study used 272 adults aged 18 to 80 with primary hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD).

Participants were randomized to receive either subcutaneous evinacumab (450 mg weekly, 300 mg weekly, or 300 mg every two weeks), intravenous evinacumab (5 mg/kg or 15 mg/kg every four weeks), or placebo, in addition to their existing lipid-lowering therapies. The study lasted 16 weeks for subcutaneous administration groups and 24 weeks for intravenous administration groups.

Key Findings:

• Efficacy: Evinacumab significantly reduced LDL-C levels across all dosing regimens compared to placebo. Additionally, the highest LDL-C reduction was observed in the intravenous 15 mg/kg every four weeks group, with a mean LDL-C reduction of 56% from baseline.

• Safety: Once again, the treatment was well-tolerated (no serious adverse effects), but had common adverse events like nasopharyngitis, influenza-like illness, and injection-site reactions.

  
  

Overall, this Phase 2 trial showed Regeneron beginning to target those with familial hypocholesteremia, but had yet to settle upon HoFH patients. With significant levels of LDL-C reduction as well as minimal side effects, its clear the Evkeeza was on the road towards success.

_{(Regeneron Pharmaceuticals, 2021)}

_{(Rosenson et al., 2024)}

• This biannual administration schedule is a major advantage, as patient tend to be more amenable to therapies that require fewer trips to a clinic.

  
  

• LEQVIO has shown a reduction of LDL-C levels by approximately 50%, providing a significant sustained therapeutic benefit for patients with HoFH.

  
  

Disadvantages

• On average, LEQVIO may take several weeks to achieve its full therapeutic effect, which could be a consideration for patients requiring rapid LDL-C reduction.

  
  

• LEQVIO is associated with higher costs (around $7200 USD a year), and its affordability/accessibility can vary based on healthcare coverage and regional approvals.

_{(LEQVIO, n.d.)}

_{(EVKEEZA Dosing and Administration, n.d.)}

_{(Regeneron Pharmaceuticals, 2021)}

REGNERON's stock price is currently priced at $762.34, reflecting a 1.7% increase from the previous close. Over the last five years, the stock has achieved a compound annual growth rate (CAGR) of 15%, which closely mirrors its annual earnings per share growth of 17%. (Stock Analysis, n.d.)

Product Pipeline and Approvals :

Dupixent, another key driver of Regeneron's market success, was developed in collaboration with Sanofi. Recently, Dupixent approved by the FDA as the first biologic treatment for COPD. Analysts estimate that this new indication could generate up to $6 billion in long term-sales. (Investor’s Business Daily, n.d.)

Strategic Developments :

Regeneron continues to expand its portfolio through strategic collaboration and innovative research, strengthening its leadership in the biotechnology industry.

_{(Regeneron Pharmaceuticals, 2023)}

Dupixent is suitable to treat: Eczema, Asthma, Chronic Rhinosinusitis and Nasal Polyps, Eosinophilic Esophagitis, and Pruigo Nodularis

Dupixent is subcutaneously injected every two or four weeks, depending on the condition and patient age, and has shown to be highly effective in reducing symptoms of Type 2 inflammatory diseases. Additionally, it provides the only steroid-free option for many chronic conditions.

_{(DUPIXENT® (Dupilumab), n.d.)}

Kevzara is suitable to treat: Severe Rheumatoid Arthritis (RA)

Kevzara is subcutaneously injected every two weeks, and significantly reduces inflammation, pain, and joint damage in RA patients. Kevzara provides an alternative for severe RA patients who do not respond to other therapies.

_{(KEVZARA® (Sarilumab), n.d.)}